Global Gallstone Solubilizing Agents Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2033

Gallstone Solubilizing Agents Market Overview

The Gallstone Solubilizing Agents Market was valued at USD 625.85 million in 2025 and is projected to reach USD 856.52 million by 2033, growing at a CAGR of 4.00% from 2026 to 2033. Market growth is supported by the rising prevalence of gallstone disease globally, increasing preference for non-surgical treatment options among patients unsuitable for cholecystectomy, and growing awareness regarding bile acid therapy for cholesterol gallstone dissolution.

The effectiveness of ursodeoxycholic acid (ursodiol) in dissolving small, radiolucent cholesterol gallstones, combined with its favorable safety profile and established clinical evidence, continues to drive prescription rates among gastroenterologists and hepatologists worldwide. The expanding indication of bile acid therapies beyond gallstone dissolution to include primary biliary cholangitis and other cholestatic liver diseases is broadening the addressable patient population and supporting market expansion. In addition, the development of improved formulations with enhanced bioavailability, growing geriatric population with higher gallstone prevalence, and increasing healthcare access in emerging markets are creating new opportunities for stakeholders across the forecast period.

Key Market Trends & Insights

• North America dominated the Gallstone Solubilizing Agents Market with the largest revenue share of 38.6% in 2025, supported by high diagnosis rates of gallstone disease, established treatment guidelines, strong reimbursement frameworks, and the presence of leading pharmaceutical manufacturers.
• Asia-Pacific is expected to be the fastest-growing region at a CAGR of 5.45% from 2026 to 2033, driven by expanding healthcare infrastructure, rising prevalence of obesity and metabolic disorders, increasing awareness of non-surgical gallstone treatment, and growing healthcare expenditure.
• The Ursodiol segment led the drug type category with a 76.8% market share in 2025, reflecting its established position as the preferred bile acid for gallstone dissolution therapy due to superior efficacy, tolerability, and extensive clinical validation.
• The Chenodeoxycholic Acid segment is anticipated to witness moderate growth during the forecast period, driven by its continued use in specific patient populations and combination therapy approaches.
• The Gallbladder Disease segment dominated the application category with a 58.4% market share in 2025, supported by the high global prevalence of cholesterol gallstones and growing preference for pharmacological dissolution in surgical non-candidates.
• The Primary Biliary Cholangitis segment is expected to witness the fastest growth during the forecast period, driven by expanding diagnosis rates, improved disease awareness, and regulatory approvals for bile acid therapies in cholestatic liver diseases.
• The Capsule segment dominated the dosage form category with a 62.3% market share in 2025, supported by established formulations, patient convenience, and favorable pharmacokinetic profiles.
• The Hospitals segment dominated the end-user category with a 45.2% market share in 2025, supported by specialist gastroenterology and hepatology departments, comprehensive diagnostic capabilities, and established treatment protocols.
• The Homecare segment is expected to witness strong growth during the forecast period, driven by the chronic nature of gallstone dissolution therapy requiring extended treatment durations of 6 to 24 months.

Market Size & Forecast

• Global Market Value (2025): USD 625.85 Million
• Expected Market Value (2033): USD 856.52 Million
• Forecast CAGR (2026–2033): 4.00%
• Leading Region in 2025: North America
• Fastest Growing Region: Asia-Pacific

Report Scope and Gallstone Solubilizing Agents Market Segmentation

Gallstone Solubilizing Agents Market Trends

Trend: Growing Preference for Non-Surgical Gallstone Management in High-Risk Patients

Clinical adoption of gallstone solubilizing agents continues to expand as healthcare providers increasingly recognize the value of pharmacological dissolution therapy for patients who are poor surgical candidates due to advanced age, multiple comorbidities, or patient preference. Bile acid therapy with ursodiol offers a non-invasive alternative to cholecystectomy for patients with small, radiolucent cholesterol gallstones and a functioning gallbladder, reducing surgical risks and healthcare costs associated with operative interventions.

For instance,

A 2025 multicenter retrospective analysis demonstrated that ursodiol therapy achieved complete gallstone dissolution in 37.2% of appropriately selected patients with small cholesterol stones (less than 10mm) over a 12-month treatment period, with an additional 28.5% achieving partial dissolution enabling conservative management.

In addition, the growing body of evidence supporting bile acid therapy for gallstone prevention in high-risk populations, including patients undergoing rapid weight loss following bariatric surgery, is expanding the prophylactic application of gallstone solubilizing agents and driving market growth beyond traditional therapeutic indications.

Gallstone Solubilizing Agents Market Dynamics

Key Market Driver: Rising Global Prevalence of Gallstone Disease

The increasing global prevalence of gallstone disease, driven by rising obesity rates, sedentary lifestyles, metabolic syndrome, and aging populations, is a primary driver of market growth. Cholesterol gallstones, which account for approximately 80% of all gallstones in Western populations, are particularly amenable to bile acid dissolution therapy, creating a substantial addressable patient population for gallstone solubilizing agents.

For instance,

According to global epidemiological data, gallstone disease affects approximately 10-15% of the adult population in developed countries, with prevalence rates increasing significantly after age 40. The World Health Organization estimates that over 20 million individuals in the United States alone have gallstones, with approximately 1 million new cases diagnosed annually. Rising prevalence of gallstone disease is expected to strengthen demand for pharmacological dissolution therapy as a non-surgical treatment alternative.

Key Restraint/Challenge: Limited Efficacy in Calcified and Large Gallstones

The restricted efficacy of gallstone solubilizing agents to small, radiolucent cholesterol gallstones with a functioning gallbladder presents a significant limitation on the addressable patient population. Ursodiol and chenodeoxycholic acid demonstrate minimal effectiveness against pigment stones, calcified stones, or stones exceeding 15-20mm in diameter, excluding a substantial proportion of gallstone patients from pharmacological treatment.

For instance,

Clinical evidence indicates that bile acid dissolution therapy requires 6 to 24 months of continuous treatment for complete gallstone dissolution, with efficacy rates declining significantly for stones larger than 10mm. The requirement for prolonged treatment duration, combined with gallstone recurrence rates of 30-50% within 5 years following successful dissolution, may limit patient and physician acceptance of pharmacological therapy compared to definitive surgical intervention.

Key Market Opportunity: Expanding Indications in Cholestatic Liver Diseases

The expanding regulatory approvals and clinical applications of ursodiol in primary biliary cholangitis (PBC), primary sclerosing cholangitis, and other cholestatic liver conditions are creating significant growth opportunities beyond traditional gallstone dissolution. Ursodiol has become the standard first-line therapy for PBC, demonstrating hepatoprotective effects, improved liver biochemistry, and delayed disease progression in clinical trials.

For instance,

The American Association for the Study of Liver Diseases (AASLD) guidelines recommend ursodiol at a dose of 13-15 mg/kg/day as first-line therapy for all patients with primary biliary cholangitis, regardless of disease stage. Growing diagnosis rates of cholestatic liver diseases and increasing awareness among hepatologists are expanding the patient population eligible for long-term bile acid therapy, supporting market growth beyond gallstone dissolution indications.

Gallstone Solubilizing Agents Market Scope

The gallstone solubilizing agents market is segmented on the basis of drug type, application, dosage form, route of administration, end-users, and distribution channel.

• By Drug Type

On the basis of drug type, the Gallstone Solubilizing Agents Market is segmented into ursodiol and chenodeoxycholic acid. The ursodiol segment dominated the market with a 76.8% market share in 2025, reflecting its established position as the preferred bile acid for gallstone dissolution therapy. Ursodiol demonstrates superior tolerability compared to chenodeoxycholic acid, with significantly lower incidence of hepatotoxicity and diarrhea, supporting its widespread adoption across therapeutic indications. The extensive clinical validation of ursodiol in gallstone dissolution, primary biliary cholangitis, and gallstone prophylaxis contributes to segment leadership, while generic availability ensures cost-effective access across global markets.

The chenodeoxycholic acid segment is expected to witness steady growth during the forecast period. Chenodeoxycholic acid continues to find application in specific patient populations and combination therapy approaches, particularly in markets where ursodiol availability is limited. The segment is also supported by ongoing research into chenodeoxycholic acid derivatives with improved safety profiles.

• By Application

On the basis of application, the Gallstone Solubilizing Agents Market is segmented into gallbladder disease, primary biliary cholangitis, and others. The gallbladder disease segment dominated the market with a 58.4% market share in 2025, driven by the high global prevalence of cholesterol gallstones and growing preference for pharmacological dissolution in patients unsuitable for surgery. The segment benefits from established treatment guidelines recommending bile acid therapy for small, radiolucent cholesterol gallstones in patients with functioning gallbladders and mild to moderate symptoms.

The primary biliary cholangitis segment is expected to witness the fastest growth from 2026 to 2033, driven by rising diagnosis rates and improved clinical awareness of the disease among hepatologists and gastroenterologists. Increased routine screening and earlier identification of liver function abnormalities are supporting timely treatment initiation. In addition, ursodiol’s well-established role as first-line therapy continues to reinforce its adoption in managing cholestatic liver conditions. Expanding access to healthcare and improved guideline-based treatment practices are further expected to drive segment growth.

• By Dosage Form

On the basis of dosage form, the Gallstone Solubilizing Agents Market is segmented into capsule, tablet, and others. The capsule segment dominated the market with a 62.3% market share in 2025, supported by established branded and generic formulations, patient convenience, and favorable pharmacokinetic profiles enabling once or twice daily dosing. Capsule formulations provide consistent drug release and absorption, supporting therapeutic efficacy in gallstone dissolution protocols.

The tablet segment held a market share of 31.4% in 2025, with ongoing development of improved tablet formulations including enteric-coated and extended-release variants. The others segment, including oral suspension formulations for pediatric patients and patients with swallowing difficulties, accounted for 6.3% of the market in 2025 and is expected to witness moderate growth during the forecast period.

• By Route of Administration

On the basis of route of administration, the Gallstone Solubilizing Agents Market is segmented into oral and others. The oral segment dominated the market with a 98.2% market share in 2025, reflecting the established oral bioavailability of bile acids and patient preference for non-invasive administration. Oral formulations enable convenient at-home administration during extended treatment durations, supporting patient compliance with therapy protocols requiring 6 to 24 months of continuous treatment.

The others segment held a market share of 1.8% in 2025, primarily consisting of investigational and specialized formulations for specific clinical scenarios.

• By End-Users

On the basis of end-users, the Gallstone Solubilizing Agents Market is segmented into hospitals, specialty clinics, homecare, and others. The hospitals segment dominated the market with a 45.2% market share in 2025, driven by specialist gastroenterology and hepatology departments, comprehensive diagnostic capabilities including imaging and bile acid composition analysis, and established treatment protocols. Hospitals serve as primary centers for initial diagnosis, treatment initiation, and monitoring of gallstone dissolution therapy.

The homecare segment is expected to witness the fastest growth in the Gallstone Solubilizing Agents Market from 2026 to 2033, driven by the chronic and long-term nature of gallstone dissolution therapy. Patients undergoing treatment often require extended medication regimens, making home-based care a convenient and cost-effective option for prescription fulfillment and administration. Increasing preference for self-management of chronic conditions, improved access to pharmaceuticals through retail and online channels, and supportive healthcare policies promoting outpatient and homecare treatment models are further accelerating segment growth.

• By Distribution Channel

On the basis of distribution channel, the Gallstone Solubilizing Agents Market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. The hospital pharmacy segment dominated the market with a 39.8% market share in 2025, supported by established procurement relationships with pharmaceutical manufacturers, comprehensive formulary management, and integration with hospital-based specialist care. Hospital pharmacies serve as primary distribution points for treatment initiation and specialist-supervised therapy.

The online pharmacy segment is expected to witness the fastest growth in the Gallstone Solubilizing Agents Market from 2026 to 2033, driven by rising adoption of digital health platforms and increasing patient preference for convenient prescription access. Home delivery services for long-term medications enhance adherence and reduce the need for frequent pharmacy visits. In addition, expanding e-pharmacy regulatory frameworks, improved telemedicine integration, and growing trust in online pharmaceutical services are supporting market expansion. Competitive pricing and broader product availability further contribute to strong segment growth over the forecast period.

Gallstone Solubilizing Agents Market Regional Analysis

North America dominated the gallstone solubilizing agents market with a revenue share of 38.6% in 2025, supported by high diagnosis rates of gallstone disease, established treatment guidelines from the American Gastroenterological Association, strong reimbursement frameworks, and the presence of leading pharmaceutical manufacturers including Teva and Allergan. Favorable regulatory pathways, robust clinical evidence supporting bile acid therapy, and extensive specialist expertise contribute to regional market leadership.

U.S. Gallstone Solubilizing Agents Market Insight

The U.S. gallstone solubilizing agents market, holding a dominant share of 82.4% within North America in 2025, benefits from the highest diagnosis rates of gallstone disease globally, extensive gastroenterology specialist networks, and strong Medicare and commercial payer reimbursement for pharmacological dissolution therapy. Academic medical centers and gastroenterology practices continue to expand bile acid therapy programs for appropriate patient populations, including surgical non-candidates and patients with primary biliary cholangitis. Generic ursodiol availability ensures cost-effective access while branded formulations maintain presence in specialty indications.

Europe Gallstone Solubilizing Agents Market Insight

The Europe gallstone solubilizing agents market held a revenue share of 31.2% in 2025 and remains a major contributor to global market growth. Strong national health system coverage for bile acid therapies, established treatment guidelines across major markets, and comprehensive hepatology specialist networks support market stability. Germany, the U.K., France, and Italy represent primary contributors to regional revenue, with growing adoption in Eastern European markets supporting expansion.

U.K. Gallstone Solubilizing Agents Market Insight

The U.K. gallstone solubilizing agents market, holding a dominant share of 18.7% within Europe in 2025, is characterized by National Health Service coverage for ursodiol therapy in gallstone dissolution and primary biliary cholangitis indications. NICE guidelines support pharmacological dissolution in appropriate patient populations, while specialist hepatology centers provide comprehensive disease management.

Germany Gallstone Solubilizing Agents Market Insight

Germany's robust healthcare infrastructure and established gastroenterology and hepatology specialist networks support comprehensive bile acid therapy programs. Dr. Falk Pharma's strong domestic presence and favorable statutory health insurance coverage contribute to high prescription volumes and market stability. Germany held a market share of 22.3% within Europe in 2025.

Asia-Pacific Gallstone Solubilizing Agents Market Insight

The Asia-Pacific gallstone solubilizing agents market is poised for rapid growth with a CAGR of 5.45% during the forecast period, driven by expanding healthcare infrastructure, rising prevalence of obesity and metabolic disorders contributing to gallstone disease, and increasing awareness of non-surgical treatment options. Japan, China, India, and South Korea represent primary growth markets, with domestic pharmaceutical manufacturers expanding generic ursodiol availability.

Japan Gallstone Solubilizing Agents Market Insight

The Japan gallstone solubilizing agents market, holding a dominant share of 28.6% within Asia-Pacific in 2025, benefits from advanced healthcare infrastructure, strong specialist expertise in hepatobiliary disease, and favorable national health insurance coverage for bile acid therapies. Established treatment protocols and comprehensive disease monitoring support optimal therapeutic outcomes.

China Gallstone Solubilizing Agents Market Insight

The China gallstone solubilizing agents market is experiencing rapid growth driven by expanding healthcare access, rising gallstone disease prevalence associated with dietary westernization and obesity, and increasing awareness of pharmacological treatment alternatives. Domestic pharmaceutical manufacturers are expanding ursodiol production capacity to meet growing demand, while specialist gastroenterology capabilities are improving in urban healthcare centers. China is expected to be the fastest-growing country in Asia-Pacific with a CAGR of 6.12% from 2026 to 2033.

Gallstone Solubilizing Agents Market Share

The gallstone solubilizing agents industry is primarily led by well-established companies, including:

• Teva Pharmaceutical Industries Ltd. (Israel)
• Viatris Inc. (U.S.)
• Lannett Company, Inc. (U.S.)
• AbbVie Inc. (U.S.)
• Epic Pharma, LLC (U.S.)
• Amneal Pharmaceuticals LLC (U.S.)
• Par Pharmaceutical (Endo International plc) (U.S.)
• Watson Laboratories, Inc. (U.S.)
• Glenmark Pharmaceuticals Ltd. (India)
• Sun Pharmaceutical Industries Ltd. (India)
• Dr. Falk Pharma GmbH (Germany)
• Daewoong Pharmaceutical Co., Ltd. (South Korea)

Latest Developments in Gallstone Solubilizing Agents Market

• In February 2026, Teva Pharmaceutical Industries Ltd. announced the expansion of its ursodiol manufacturing capacity at its North American facilities to meet growing global demand for bile acid therapies. The expansion supports Teva's position as a leading supplier of generic ursodiol formulations worldwide.
• In November 2025, Dr. Falk Pharma GmbH received European Medicines Agency approval for an extended-release ursodiol formulation designed to improve patient compliance through once-daily dosing in primary biliary cholangitis treatment. The approval supports improved adherence in chronic bile acid therapy.
• In August 2025, Sun Pharmaceutical Industries Ltd. launched its ursodiol 500mg capsule formulation in multiple Asian markets, expanding patient access to bile acid therapy for gallstone dissolution and cholestatic liver diseases in the region.
• In May 2025, Amneal Pharmaceuticals LLC announced FDA approval for its ANDA submission for ursodiol capsules 300mg, expanding generic competition and supporting cost-effective patient access in the United States market.
• In January 2025, Glenmark Pharmaceuticals Ltd. received regulatory approval from the Drugs Controller General of India for its ursodiol tablet formulation, supporting expanded domestic manufacturing capacity and improved patient access to gallstone dissolution therapy in India.
• In October 2024, Allergan plc (AbbVie Inc.) announced positive Phase IV clinical data demonstrating long-term safety and efficacy of ursodiol therapy in primary biliary cholangitis patients over a 10-year follow-up period, supporting continued use in chronic cholestatic liver disease management.
• In July 2024, Lannett Company, Inc. announced the resumption of ursodiol capsule production at its facilities following manufacturing optimization, ensuring continued supply of generic bile acid therapies to the U.S. market.
• In March 2024, Daewoong Pharmaceutical Co., Ltd. announced the initiation of clinical studies evaluating ursodiol in combination with novel hepatoprotective agents for enhanced efficacy in primary biliary cholangitis patients with suboptimal response to monotherapy.

SKU-68130